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To evaluate the incidence of inconclusive bone scans and down-stream imaging and 
clinical follow-up generated, including subsequent treatment outcomes in men 
affected by inconclusive bone scans with intermediate and high-risk prostate cancer.   
Data source 
Retrospective study of clinical data for a Scottish population of men diagnosed with 
prostate cancer in the intermediate-risk and high-risk groups. 
Conclusion 
Of the 1246 patients included, initially 81 men were identified as having an 
inconclusive bone scan result following multidisciplinary team discussion. After 
further imaging 24 patients remained inconclusive for metastasis. Of these patients, 
two patients received no treatment; one due to decision of watchful waiting, and one 
due to death. Of the 13 patients receiving radical treatment (LRP or RT), three 
patients showed relapse (23%) indicating presence of microscopic disease, and failure 
of radical treatment alone for these patients. 
Implications for Nursing Practice  
This paper will assist nurses and multidisciplinary team members in understanding 
how patients diagnosed with intermediate and high-risk prostate cancer with 
© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license 
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inconclusive bone scan results are subsequently imaged and managed in the current 
healthcare system. This raises awareness amongst nursing staff of disease recurrence 
and possibility of downstream multimodality treatment for these men with 
inconclusive bone scans.   
 
Introduction 
Men diagnosed with localized prostate cancer are stratified into three categories: low, 
intermediate or high-risk. The stratification is based on the Prostate-Specific Antigen 
(PSA) value, Gleason score and the clinical stage as defined by National Institute for 
Health and Care Excellence (NICE). These categories are: low-risk: PSA <10 ng/ml 
and, Gleason score ≤6 and T1 to T2a, intermediate-risk: PSA 10-20 ng/ml or, Gleason 
score 7 or, T2b and high-risk: >20 ng/ml or, Gleason score 8-10 or, ≥T2c. 1 The risk 
stratification guides further diagnostic pathways and treatment. Metastatic prostate 
cancer is commonly diagnosed by bone scintigraphy, also called isotope bone scans, 
or just bone scans, see figure 1. Bone scans remains a cornerstone of prostate cancer 
staging investigations and the issue of inconclusive bone scan results due to a lack of 
sensitivity and specificity warrants further investigation on real-world patient 
outcomes.  
 
(Fig. 1 here) 
 
Current NICE guidelines do not recommend bone scan to men with low-risk localized 
prostate cancer.1 Multidisciplinary teams (MDTs) continues to recommend  a bone 
scan to all men stratified to either intermediate or high-risk prostate cancer groups. 1 
Importantly, bone scan results facilitate clinical decision-making based upon the 
Tumor Node Metastasis (TNM) classification.2 Broadly, localized or locally advanced 
treatments options include prostatectomy, radiotherapy, radiotherapy and 
neoadjuvant/adjuvant androgen deprivation therapy, or metastatic prostate cancer has 
the treatment intent of palliation in the form of hormonal manipulation, chemotherapy 
and 2nd generation hormones such as Abiraterone + prednisolone or Enzalutamide.3 
The main treatment goal for a man diagnosed with metastatic prostate cancer, is 
disease control and optimization of quality of life.4  
 
The main stay treatment for metastatic prostate cancer, is castration either by reducing 
systematic testosterone levels by surgical or chemical induced. 3 ADT can result in 
profound physical and psychological decrements in health which can negatively effect 
quality of life and may increased the requirement for supportive care intervention.5 
Side effects commonly grappled with include: body feminization, changes in sexual 
performance, relationship changes, cognitive and affective symptoms and fatigue, 
sleep disturbance, and depression.6-15 Following treatment, biochemical recurrence is 
classified when a PSA value continues to rise (greater than 0.2 ng/mL after treatment 





It is commonly observed in MDTs that some patients diagnosed with prostate cancer 
have inconclusive bone results. When clinicians receive imaging results for their 
patients, they must rely on interpretation by imaging experts.  However, a conclusion 
of a bone scan may not always be definitive, and in many cases the bone scan will 
determine the treatment decisions for patients, recommended across all clinical 
urological guidelines. 1,3 Fundamentally, inconclusive bone scans remains a 
contemporary challenge for the multidisciplinary team in risk stratifying men to 
evidence-based treatment options. Clinicians require definitive answers from imaging 
about their patients, but some lesions can be difficult to interpret. Thus, the avid bone 
lesion may not represent per se a skeletal metastasis, which will condemn men to 
palliative treatment rather than curative intent.  A recent systematic review of 
inconclusive bone scans in the clinical trial setting underscored a lack of real-world 
data in routine clinical practice in how this dilemma is managed.11  
  
There are several studies describing the outcome of conclusive bone scans for 
metastatic status in men with prostate caner 11,17-22 but seldom published clinical data 
exists on the clinical consequences of inconclusive bone scans on patient 
outcomes.12,13,15,23,24 A study13 reported that 58 of 459 patients (13%) affected by 
prostate cancer were found to have inconclusive bones scans. Furthermore, a study 
elsewhere23 observed 50 of 366 (13%) of patients in their series had inconclusive 
bones scan reported.  However, neither of these studies provided clarification on 
subsequent follow-up imaging modalities to establish whether or not these patients 
had metastatic or non-metastatic disease. Accurate TNM staging in men with prostate 
cancer has a direct causal relationship with morbidity and mortality.  
 
However, evidence15 identified 55 of 420 (13%) patients have inconclusive features in 
bone scan results reported, of which 40 patients (of the 55 patients) had further 
imaging, namely Magnetic Resonance Imaging (MRI), Computed Tomography (CT) 
and x-ray to clarify metastatic status. The report of subsequent imaging identified that 
all 40 patients with inconclusive bone scans who had subsequent imaging were found 
to be consistent with non-metastatic disease. Importantly, this study did not report on 
the remaining 15 patients who had inconclusive bone scan with no follow-up imaging 
and their oncological outcomes for further imaging interventions.  Clinically, this 
information is important to ensure correct TNM classification and evidence-based 
MDT treatment recommendations.1,3 
 
Based upon the existing available research in this area, studies have consistently 
reported a prevalence of 13% of inconclusive bone scans being reported.13-15  
Importantly, data has not reported how this clinical dilemma is solved in clinical 
practice, or how patients are counseled in the complex treatment decision-making 
process in this uncertain scenario. While bone scans may be replaced with more 
accurate imaging methods, the experience of inconclusive bone scans remains a 
problem in contemporary practice. Prostate cancer specialist nurses and MDT 
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colleagues will encounter the occurrence of inconclusive bone scans routinely in their 
MDT meetings and this article provides an account of existing practice and important 
clinical outcomes. We used real world clinical data to report on the incidence of 
inconclusive bone scans, clinical interventions and subsequent patient outcomes to 
inform important lessons learned in prostate cancer treatment and care.  
 
Patients and Methods 
 
Study Design: Retrospective case note review and electronic data linkage. 
 
Data source: 
This study received local Caldecott approval (Caldicott/IGTCAL2920+). Data 
collection was retrospective for all patients diagnosed with prostate cancer 
(intermediate- or high-risk groups) between January 2010 and December 2016, within 
the National Health Service (NHS) Tayside in Scotland, United Kingdom (UK). The 
NHS Tayside health board is one of the fourteen Scottish Health authorities 
responsible for the delivery of healthcare in the Scottish population.  Every resident in 
the geographical location of Tayside is registered with the health authority and has a 
ten-digit Community Health Index (CHI) number as a unique identifier across all 
health records including primary and secondary care settings. This Unique Identifier 
was used to link data on outcome of men with inconclusive bone scans in this study.   
All patients with a suspected prostate cancer are discussed in NHS Tayside’s MDT 
and detailed documented MDT outcomes are securely managed on Tayside 
Urological Cancers Network Database. The cohort identified, was stratified into either 
intermediate- or high-risk according to EAU guidelines.3 The CHI number was used 
to cross link electronic databases to obtain the following data: age at the time of 
diagnosis, PSA value, Gleason score and clinical T-stage, in addition to outcome of 
bone scan, results of concurrent and subsequent imaging (due to inconclusive bone 
scan results) and treatment decisions for patients with inconclusive bone scans.  
 
Patient selection: 
Inclusion criteria:  All consecutive histologically proven prostate cancer was included.  
Histological Gleason score, PSA and clinical T-stage were used to classify men as 
intermediate or high-risk groups during 2010 and 2016.  This was based upon MDT 
consensus and discussion as recommended by guidelines from the National Institute 
for Health and Care Excellence 1 as defined by D’Amico. 25 All the included men 
subsequently had a bone scan performed as part of their cancer staging. Exclusion 
criteria: men in the low-risk group, and those who did not have a bone scan, outcome 
of bone scan, and clinical stage available for evaluation.  
 
Bone scans: 
The procedure for bone scans involves 99mTc Hydroxymethylene diphosphatenate 
(600 MBq, 2-3 ml with NaCl 0.9%) to be injected intravenously, and imaging 
performed 2-5 hours post-administration. Anterior and posterior images were 
 5 
obtained using a large field-of-view dual head gamma camera (NHS Tayside have 
three gamma cameras of the following make: GE Discovery, GE Infinia and Phillips 
Brigthview). Several radiologists with nuclear medicine training reported the bone 
scans. All bone scans were reviewed at MDT meetings and the expert (dedicated uro-
radiologist with more than 5 years of experience) interpretation were documented in 
the Tayside Urological Cancers Network Database.   
 
Clinical follow-up: 
For patients who received radical prostatectomy, PSA > 0.2 ng/mL was considered as 
biochemical recurrence.16 For patients who received radiotherapy (RT), two 
consecutive PSA results ≥2.0 ng/mL higher than the PSA nadir value was considered 
treatment failure.26 For patients who received ADT, castrate resistant disease was 
considered when PSA values had three consecutive rises in PSA one week apart, 
resulting in two 50% increases over the nadir, with PSA >2 ng/mL or radiographic 
appearance of two or more bone lesion.3  
 
Statistical analysis: 
Data was entered into SPSS version 22.0.  Categorical data was examined by the 
proportion of patients stratified into the intermediate or high-risk group. Descriptive 
analysis was performed and the proportion of men in each group was calculated as 
positive, negative or inconclusive for bone metastases.  
 
Results 
Data was collected for a total of 1246 patients. The mean age was 71.8 years, 
(minimum 45.1 years, maximum 99.2 years). MDT consensus identified 341 patients 
in the intermediate-risk group and 905 in the high-risk prostate cancer group.  The 
distribution of patients stratified into intermediate- or high-risk per annum are detailed 
in Table 1.  
 
(Table 1 here) 
 
A higher proportion of patients were negative for bony metastasis (90.3%, n=308, for 
the intermediate-risk group and 64.9%, n=587 for the high-risk group), see figure 2. 
Moreover, 28.3% (n = 256) of men were positive for metastasis in the high-risk group 
compared to 4.1% (n = 14) in the intermediate-risk group. The proportion of patients 
with inconclusive bone scans was comparable between the intermediate-risk group 
and the high-risk group (5.6%, n=19 vs. 6.9%, n=62), see figure 2 and Table 2. 
 
(Fig. 2 here) 
 
 
(Table 2 here) 
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Patients with inconclusive bone scans reports (n = 81) were followed up with further 
imaging. Follow-up imaging included x-ray, CT or MRI scans. This identified that 
bone metastasis were negative for 68.4% (n = 13) for the intermediate-risk group and 
48.4% (n = 30) for the high-risk group. Patients identified to have positive clinical 
evidence of metastatic disease was 5.3% (n = 1) for the intermediate-risk group and 
21% (n = 13) for the high-risk group. Patients that remained inconclusive despite 
follow-up imaging were for the intermediate risk-group, 26.3% (n = 5) and for the 
high-risk group this were 30.6% (n = 19), see Table 3.  
 
(Table 3 here) 
 
The most frequent site location of abnormal tracer uptake, which remained 
inconclusive on subsequent imaging, was a single location on a rib, see Table 4. 
 
(Table 4 here) 
 
Of the 24 patients who had inconclusive bone scans, five patients had no further 
imaging, one patient had x-ray only, five patients had CT and eight patients had MRI 
as follow-up. Three patients had x-ray and MRI, one patient had both CT and MRI 
and lastly one patient had x-ray and CT follow-up, see figure 3. 
 
(Fig. 3 here) 
 
The 24 patients who remained inconclusive for metastatic status despite subsequent 
imaging were followed up to identify treatment outcomes.  Five of the 24 patients had 
radical prostatectomy, eight patients had RT, nine patients had ADT alone and two 
patients had no treatment, one due to watchful wait and one due to death with 
unknown case, see figure 4.  
 
(Fig. 4 here) 
 
The outcome of the treatment of the 24 patients is summarized in figure 5. Summary 
of patient demographic, treatment and outcome are shown in Table 5. For the five 
patients in the intermediate-risk group, one patient was treated with LRP and had 
biochemical relapse (patient number 595), the remaining four were treated with RT 
and ADT with no biochemical relapse (patients 334, 442, 790 and 1073).  
 
For the 19 patients in the high-risk group, eight patients received radical treatment 
(LRP or RT +/- ADT), of which two patients had biochemical relapse requiring 
salvage therapy (patients 572 and 812), and one developed metastatic castrate 
resistant disease and received chemotherapy (patient 622). Arguably patient number 
622 already had metastatic disease to start with. 
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Of the remaining 11 patients, nine received indefinite ADT. Three patients developed 
castrate resistant disease (patients numbers: 328, 644 and 792) with the remaining six 
patients continued to respond to hormones (patients 637, 746, 765, 816, 1029 and 
1165). Two patients received no treatment, one due to a decision of watchful waiting 
(patient 940), and one due to death of unrelated cause (patient 1033).    
 
(Fig. 5 here) 
 
 




This retrospective study used real world clinical data to report on the incidence of 
inconclusive bone scans, clinical interventions and subsequent patient outcomes to 
inform important lessons learned in prostate cancer care. This study consisted of 1246 
patients, 81 of which were initially diagnosed with inconclusive bone metastasis. 
Following further imaging, 24 patients remained inconclusive of metastatic disease.  
This represents a challenge in clinical practice, and handling of patients with 
inconclusive imaging results can vary widely. Our study provides an important 
contribution by detailing the frequency of inconclusive bone scan results and how 
these were managed in clinical practice, which to the best of our knowledge have not 
been accurately documented before. 
 
The key finding of this study was that a small but clinically important proportion of 
men with prostate cancer in high- and intermediate-risk group show inconclusive 
bone scan results. These men had aggressive disease and needed further imaging to 
clarify appropriate treatment pathways. However, five men did not receive further 
imaging to accurately diagnosis the definitive TNM staging. Observations from this 
study underscore the importance of urgent consensus on imaging protocol in these 
situations including generation of further evidence.   
 
There are several clinical implications of the study findings. Firstly, incidence of 
positive bone scan was higher in our cohort. A recent study17 reported on men 
diagnosed with prostate cancer and categorized into three risk groups for the outcome 
of bone scans. This study showed that 31% of patients placed in the low-risk group, 
48% in the intermediate risk-group and 62% in the high-risk group had a bone scan 
respectively. Of the patients with a bone scan that proved positive for bone 
metastases, the results were 0.3% in the low-risk group, 1.1% in the intermediate risk 
group and 14% in the high-risk group.17 Despite the fact that the study by Falchook et 
al. 17 had a total patient number of 47,224 of which 23,564 individuals received a 
bone scan, there was no mention of patients with inconclusive bone scans. The study 
only mentioned those patients who are positive for metastasis. The study by Falchook 
et al. 17 concludes that bone scans are overused in the intermediate-risk group and 
underused in the high-risk group. Our study found a higher incidence of patients 
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positive for bone metastasis in both the intermediate-risk group (4.1%) and in the 
high-risk group (28.3%) compared to the study of Falchook et al. 17 As such, our 
study indicates that for the intermediate-risk group nearly 96% of patients potentially 
did not need a bone scan and for the high-risk patient group this was nearly 62%. The 
difference may be attributable to prevalence of screened population for prostate 
cancer detection.   
 
Secondly, in contrast to our study, one study15, reported a  proportion of men (55 out 
of 420; 13%) having inconclusive features from their bone scan, from which 40 
patients received follow-up radiographic imaging to clarify metastatic status. All of 
these patients were from the follow-up imaging considered negative and hence this 
study reported no patients who remained inconclusive on the basis of their bone 
scan.15 This underscores importance of downstream follow-up imaging to clarify 
lesions in men with inconclusive metastatic disease on bone scans.   
 
Thirdly, the inconclusive bone scan generates a care pathway for men which has cost 
implications.  The cost involved in performing a bone scan is not available for NHS 
Tayside as there is no treatment of private patients. Costs by hospitals conducting this 
investigation for private patients are set to about £363 per scan.27 This means, that if 
patients in this cohort who was negative for metastasis (895 patients, Table 2) could 
avoid having a bone scan, as indicated by other predictors, then over the seven-year 
period a total of £324,885, or an annual cost of £55,147, could be redistributed for 
other use.  
 
Fourthly, guidelines for further imaging in men with inconclusive bone scan in 
prostate cancer are not clear. In the present study, men with inconclusive bone scans 
had a variation of follow-up imaging (Figure 2), which reflects lack of consensus and 
guidelines in this area of clinical practice. The main follow-up imaging used was CT 
or MRI. Other imaging modalities for identifying bone metastasis are: Positron-
emission tomography (PET), Single-photon emission computed tomography (SPECT, 
or hybrid imaging techniques such as SPECT/CT, PET/CT, PET/MRI.  
PET scanning is reported as having a sensitivity of 98% and specificity of 56%, and 
SPECT having a sensitivity of 87% and a specificity of 91%, as well as PET/CT 
having a sensitivity of 100% and specificity of 97%. 12 Whole body MRI was found 
to have a sensitivity of 91% and a specificity of 95% 28, however a whole body MRI 
scan require a patient to be supine and not moving while strapped down by coils 
around head and torso including arms and lower body 29 for a minimum of an hour or 
more.30 A meta-analysis comparing MRI, PET, PET/CT and bone scans found PET 
and PET/CT to be superior to MRI and bone scans in identifying bone metastasis. 31 It 
is acknowledged that these imaging modalities are expensive and with limited 
accessibility. This research shows that for this patient cohort of the seven years 
included, nearly 2% of patients (24 our of 1246 patients) had a bone scan of 
inconclusive results. This being a small population, adds to the argument that this 
patient group should be recommended for the more sensitive and specific imaging 
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modalities despite them being more expensive and lesser accessible. Recommending 
patients diagnosed with prostate cancer and inconclusive bones scans for more 
elucidatory imaging modalities will deliver an optimum treatment and care for this 
patient group. 
 
Finally, the new imaging methods need further evaluation in a clinical setting of 
inconclusive bone scans. Prostate-specific membrane antigen (PSMA) secreted and 
expressed on the cell walls of almost all Prostate Carcinoma (PCa) tumors. These 
proteins have been targeted with gallium 68, 99mTc tracer. 32 The PET scan based on 
this tracer (Ga68-PSMA) has been shown to have better diagnostic accuracy 
compared to Choline and acetate PET scans in detecting extra-prostatic disease, along 
with lymph node and bone lesions in prostate cancer. 32 Furthermore, promising 
results are seen in staging of prostate cancer disease 33 and in those with recurrences 
following hormonal treatment. 34 It is essential that future studies are designed to 
assess the role of this new imaging modality in men with inconclusive bone scans.   
This study nevertheless has allowed evaluation of current practices for treatment of 
men diagnosed with prostate cancer with inconclusive bone scans. The challenge of 
dealing with inconclusive bone scans in otherwise fit and healthy men for radical 
treatment remains a real one.  
 
Limitations to the study: 
This is a retrospective study with its associated biases including selection of cohort.  
The design of exclusion introduces a minor selection bias in the study and needs to be 





Diagnostic imaging can cause cancer-related distress, a condition known as 
“scanxiety”. Men are fearful of treatments, progression of disease and distress caused 
by the requirement for additional imaging to re-assess disease status, such as 
inconclusive bone scans.  Men may experience sadness, anger, fear, dread, confusion 
and anxiety.  Men affected by scanxiety can occur weeks before and follow-up scans 
(x-ray, CT scan, MRI).  Prostate Cancer Specialist Nurses should keep an open 
dialogue when discussing coping strategies and feelings with their patients. The 
importance of routine implementation of holistic needs assessment in practice is 
required to identify men who are at clinical risk of scanxiety and provide appropriate 




The present study has shown nearly 2% (1.92%) incidence of inconclusive bone scan 
results in men with intermediate- and high-risk non-metastatic prostate cancer.   
Although small in number, these men do need alternate improved diagnostic 
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pathways and better imaging modalities in order to get a better risk stratification for 
further treatment. There is a need for consensus and evidence generation through 
further research in this area, in particular evaluation of whole body MRI and Ga68-
PSMA scans. 
 
Compliance with Ethical Standards 
This research did not receive any specific grant from funding agencies in the public, 
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